Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27349808 | 0.87 | GPR119 (0.42) | GPR119USP30STS | |
| SCHEMBL27349825 | 0.87 | GPR119 (0.42) | GPR119 | |
| SCHEMBL31727646 | 0.87 | GPR119 (0.42) | GPR119USP30STS | |
| SCHEMBL27349793 | 0.87 | GPR119 (0.42) | GPR119USP30STS | |
| SCHEMBL27349821 | 0.87 | STS (0.42) | GPR119USP30STS | |
| SCHEMBL27349835 | 0.86 | OPRM1 (0.57) | OPRM1OGFRL1OPRD1OPRK1GPR119 | |
| SCHEMBL31634398 | 0.86 | CYP1A2 (0.38) | OPRM1OGFRL1OPRD1OPRK1 | |
| SCHEMBL27349842 | 0.86 | GPR119 (0.41) | GPR119USP30STS | |
| SCHEMBL27349830 | 0.85 | STS (0.46) | GPR119USP30STS | |
| SCHEMBL27351552 | 0.80 | CYP1A2 (0.37) | OPRM1OGFRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | OPRM1 4336/4885OGFRL1 4314/4885OPRD1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.